RxDoctor Payments DataLook up a doctor →

Ronald George

Rheumatology · Wilmington, NCNPI 1265657894

Payments from drug & device makers

$1,029,173in general payments, 2019–2025

Across 1,463 payments — averaging $703.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$388K
  • Sun Pharmaceutical Industries Inc.$263K
  • Eli Lilly$251K
  • AbbVie$99K
  • E.r. Squibb & Sons, L.L.C.$13K
  • Gilead$5K
  • plus $11K from 31 others
$276in research payments, 2019–2025

Across 2 payments — averaging $138.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$276

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,029,173 in reported general payments places this provider in the 95th percentile of 210 rheumatology providers in North Carolina.

See all rheumatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$2,238,881
Medicare patients
766
Services billed
190,738

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other rheumatology in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →